BlackRock
TXG icon

BlackRock’s 10x Genomics TXG Stock Holding History

BlackRock’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414M Buy
10,804,070
+724,157
+7% +$19M 0.01% 1352
2026
Q1 		$214M Buy
10,079,913
+65,451
+0.7% +$1.31M ﹤0.01% 1630
2025
Q4 		$163M Buy
10,014,462
+554,353
+6% +$8.37M ﹤0.01% 1817
2025
Q3 		$111M Buy
9,460,109
+25,613
+0.3% +$334K ﹤0.01% 2046
2025
Q2 		$109M Buy
9,434,496
+2,766,674
+41% +$25.2M ﹤0.01% 1984
2025
Q1 		$58.2M Sell
6,667,822
-102,429
-2% -$1.29M ﹤0.01% 2297
2024
Q4 		$97.2M Sell
6,770,251
-45,119
-0.7% -$712K ﹤0.01% 2102
2024
Q3 		$154M Buy
6,815,370
+422,720
+7% +$8.74M ﹤0.01% 1813
2024
Q2 		$124M Buy
6,392,650
+385,007
+6% +$10.1M ﹤0.01% 1900
2024
Q1 		$225M Buy
6,007,643
+302,251
+5% +$13.3M 0.01% 1571
2023
Q4 		$319M Buy
5,705,392
+219,098
+4% +$9.53M 0.01% 1333
2023
Q3 		$226M Buy
5,486,294
+83,338
+2% +$4.34M 0.01% 1451
2023
Q2 		$302M Buy
5,402,956
+163,849
+3% +$8.87M 0.01% 1289
2023
Q1 		$292M Sell
5,239,107
-80,517
-2% -$3.76M 0.01% 1284
2022
Q4 		$194M Buy
5,319,624
+227,061
+4% +$7.42M 0.01% 1551
2022
Q3 		$145M Sell
5,092,563
-1,729,685
-25% -$65.9M ﹤0.01% 1713
2022
Q2 		$309M Sell
6,822,248
-2,334,744
-25% -$121M 0.01% 1208
2022
Q1 		$697M Buy
9,156,992
+1,138,358
+14% +$99.6M 0.02% 753
2021
Q4 		$1.19B Sell
8,018,634
-336,042
-4% -$51.5M 0.03% 538
2021
Q3 		$1.22B Buy
8,354,676
+805,501
+11% +$138M 0.03% 501
2021
Q2 		$1.48B Buy
7,549,175
+2,242,036
+42% +$406M 0.04% 448
2021
Q1 		$961M Buy
5,307,139
+144,119
+3% +$24.9M 0.03% 600
2020
Q4 		$731M Buy
5,163,020
+1,874,510
+57% +$272M 0.02% 666
2020
Q3 		$410M Buy
3,288,510
+1,584,772
+93% +$166M 0.02% 868
2020
Q2 		$152M Buy
1,703,738
+1,238,609
+266% +$96.5M 0.01% 1554
2020
Q1 		$29M Buy
465,129
+107
+0% +$8.35K ﹤0.01% 2402
2019
Q4 		$35.5M Sell
465,022
-448,320
-49% -$27M ﹤0.01% 2565
2019
Q3 		$46M Buy
+913,342
New +$50.5M ﹤0.01% 2342

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock's TXG Position: Q2 2026 in Review

BlackRock increased its 10x Genomics (TXG) stake by 7.2% in Q2 2026, buying an estimated $19M and bringing the position to 10,804,070 shares worth $414M. The position accounts for 0.01% of the portfolio, ranked #1352.

BlackRock first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.48B in Q2 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • BlackRock held 10,804,070 shares of 10x Genomics worth $414M as of Q2 2026.
  • BlackRock bought 724,157 10x Genomics shares in Q2 2026, an estimated $19M.
  • 10x Genomics made up 0.01% of BlackRock's portfolio in Q2 2026, its #1352 holding.
  • BlackRock first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • BlackRock's 10x Genomics position peaked at $1.48B in Q2 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.